Article
Oncology
Chihao Zhang, Jiayun Lin, Xiaochun Ni, Hongjie Li, Lei Zheng, Zhifeng Zhao, Xiaoliang Qi, Haizhong Huo, Xiaolou Lou, Qiang Fan, Meng Luo
Summary: The study found a negative association between high OPG levels and survival rates in HCC patients, indicating OPG as a potential prognostic predictor for those undergoing radical resection. This association was further confirmed in specific subgroups.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Qingli Li, Tianqiang Song
Summary: Although adjuvant sorafenib therapy for patients with HCC and high recurrence risk does not reduce the recurrence risk of HCC, it might be associated with longer survival and a lower risk of death.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Tzu-Rong Peng, Chao-Chuan Wu, Sou-Yi Chang, Yen-Chih Chen, Ta-Wei Wu, Ching-Sheng Hsu
Summary: This study investigated the therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable HCC. The findings showed that the combination therapy resulted in better overall survival outcomes compared to sorafenib alone.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Jiaqi Han, Xiaomeng Lan, Kun Tian, Xi Shen, Jinlan He, Nianyong Chen
Summary: A study evaluated the cost-effectiveness of capecitabine as maintenance therapy for patients with newly diagnosed metastatic nasopharyngeal carcinoma (mNPC). The results showed that capecitabine maintenance therapy after induction chemotherapy was cost-effective, providing additional life quality and duration at a relatively low cost.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Gastroenterology & Hepatology
Lorena Carballo-Folgoso, Rut Alvarez-Velasco, Rebeca Lorca, Andres Castano-Garcia, Javier Cuevas, Maria Luisa Gonzalez-Dieguez, Maria Martin, Carmen Alvarez-Navascues, Valle Cadahia, Cesar Moris, Manuel Rodriguez, Maria Varela
Summary: The study assessed the frequency and management of cardiovascular events in HCC patients treated with sorafenib, revealing a higher-than-expected incidence of cardiovascular events. Furthermore, the CARDIOSOR scale proved helpful in identifying patients at higher risk of MACE.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Andrea Casadei-Gardini, Mario Scartozzi, Toshifumi Tada, Changhoon Yoo, Shigeo Shimose, Gianluca Masi, Sara Lonardi, Luca Giovanni Frassineti, Silvestris Nicola, Fabio Piscaglia, Takashi Kumada, Hyung-Don Kim, Hironori Koga, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Yeonghak Bang, Masanori Atsukawa, Takuji Torimura, Kunihiko Tsuj, Ei Itobayashi, Hidenori Toyoda, Shinya Fukunishi, Lorenza Rimassa, Margherita Rimini, Stefano Cascinu, Alessandro Cucchetti
Summary: The study used data from common clinical practice to investigate the equivalence between sorafenib and lenvatinib for unresectable hepatocellular carcinoma. The analysis found no significant survival advantage of lenvatinib over sorafenib in the overall cohort, but suggested potential benefits of lenvatinib in patients who had previous treatment with TACE, PS score of 0, or no extrahepatic disease.
LIVER INTERNATIONAL
(2021)
Article
Oncology
I-Cheng Lee, Yee Chao, Pei-Chang Lee, San-Chi Chen, Chen-Ta Chi, Chi-Jung Wu, Kuo-Cheng Wu, Ming-Chih Hou, Yi-Hsiang Huang
Summary: The determinants of response and survival in patients with hepatocellular carcinoma (HCC) receiving regorafenib remain unclear. This study aimed to delineate the determinants of response and survival after regorafenib and evaluate post-progression treatment and outcomes. The study found that preserved liver function and next-line therapy are important prognostic factors after regorafenib failure.
Article
Biochemistry & Molecular Biology
Bin-Yan Zhong, Zhi-Ping Yan, Jun-Hui Sun, Lei Zhang, Zhong-Heng Hou, Xiao-Li Zhu, Ling Wen, Cai-Fang Ni
Summary: This study used a machine learning approach based on the RF model to predict one-year disease control for patients with HCC treated with TACE combined with sorafenib, and identified several independent risk factors. The RF model achieved a higher concordance index compared to the logistic regression model, indicating its accuracy in predicting disease control.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Urology & Nephrology
Petros Grivas, Evgeny Kopyltsov, Po-Jung Su, Francis X. Parnis, Se Hoon Park, Yoshiaki Yamamoto, Peter C. Fong, Christophe Tournigand, Miguel A. Climent Duran, Aristotelis Bamias, Claudia Caserta, Jane Chang, Paul Cislo, Alessandra di Pietro, Jing Wang, Thomas Powles
Summary: This study compared the efficacy of first-line maintenance plus best supportive care with that of best supportive care alone in patients with advanced urothelial carcinoma. The results showed that the addition of first-line maintenance treatment significantly prolonged overall survival and had a minimal impact on quality of life.
Article
Immunology
Yamin Shu, Ying Tang, Yufeng Ding, Qilin Zhang
Summary: This study aimed to evaluate the cost-effectiveness of nivolumab vs sorafenib as first-line therapy for advanced HCC from the perspective of Chinese healthcare system. The results showed that nivolumab could provide more health benefits compared with sorafenib, but was estimated not to be cost-effective at the commonly adopted WTP threshold in China.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Baek-Yeol Ryoo, Philippe Merle, Amit S. Kulkarni, Ann-Lii Cheng, Mohamed Bouattour, Ho Yeong Lim, Valeriy Breder, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Bruno Daniele, Josephine M. Norquist, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Richard S. Finn, Masatoshi Kudo
Summary: Pembrolizumab preserved health-related quality of life during treatment for advanced hepatocellular carcinoma. The positive benefit/risk profile of pembrolizumab in a second-line treatment setting for patients who previously received sorafenib is supported by these findings in combination with efficacy and safety results.
Article
Oncology
Zhancheng Qiu, Weili Qi, Youwei Wu, Lingling Li, Chuan Li
Summary: This study examines the impact of public insurance status on the survival outcomes of HCC patients after liver resection in China. The results show that underinsured HCC patients have worse survival outcomes after liver resection. This may be due to the limited access to care for underinsured patients, but further exploration is needed for conclusive evidence.
Article
Multidisciplinary Sciences
Liming Zheng, Xi Gu, Guojun Zheng, Xin Li, Meifang He, Longgen Liu, Xike Zhou
Summary: The study constructed a predictive model using various analysis methods to successfully identify high-risk patients for early HCC recurrence, and predict patients' response to adjuvant sorafenib treatment. The model can optimize risk stratification for early HCC recurrence and evaluate patient response to adjuvant sorafenib after liver resection.
Article
Oncology
Anna Soria, Mariona Calvo, Meritxell Casas, Zara Vidales, Sergio Munoz-Martinez, Victor Sapena, Marc Puigvehi, Lidia Canillas, Raquel Guardeno, Adolfo Gallego, Beatriz Minguez, Diana Horta, Ariadna Clos, Silvia Montoliu, Merce Roget, Maria Reig, Mercedes Vergara
Summary: This study characterized elderly patients treated with sorafenib and found that it is safe for this population. The findings provide valuable information for the use of atezolizumab-bevacizumab in elderly candidates.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, Xiaoyu Chen
Summary: While nivolumab improves overall survival and has fewer adverse events compared to sorafenib for the treatment of advanced hepatocellular carcinoma, it is not cost-effective from a third-party payer perspective in the United States. However, favorable cost-effectiveness may be achieved if the price of nivolumab is substantially reduced.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Genetics & Heredity
Yan Yan, Wen He, Yonghua Chen, Qiang Li, Jiahao Pan, Yunfei Yuan, Weian Zeng, Dongtai Chen, Wei Xing
Summary: The expression of SCN4A and SCN7A has been found to undergo significant and stable changes in hepatocellular carcinoma (HCC). The expression of SCN7A has better prognostic value and may participate in the progression of HCC.
FRONTIERS IN GENETICS
(2022)
Article
Medicine, Research & Experimental
Xiao-ping Tan, Kai Zhou, Qing-li Zeng, Yun-fei Yuan, Wei Chen
Summary: This study compared the clinical and prognostic features of non-B non-C alpha-fetoprotein (AFP)(-)-hepatocellular carcinoma (HCC) patients with other groups. The study found that non-B non-C alpha-fetoprotein (AFP)(-)-HCC patients had a favorable prognosis and could serve as a marker for predicting the risk of tumor recurrence in the early stages.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Correction
Oncology
Chenwei Wang, Yadi Liao, Wei He, Hong Zhang, Dinglan Zuo, Wenwu Liu, Zhiwen Yang, Jiliang Qiu, Yichuan Yuan, Kai Li, Yuanping Zhang, Yongjin Wang, Yunxing Shi, Yuxiong Qiu, Song Gao, Yunfei Yuan, Binkui Li
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Alissa Michelle Wong, Xiaofan Ding, Aikha Melissa Wong, Mingjing Xu, Luyao Zhang, Howard Ho-Wai Leung, Anthony Wing-Hung Chan, Qi Xiu Song, Joseph Kwong, Loucia Kit-Ying Chan, Matthew Man, Mian He, Jinna Chen, Zhe Zhang, Wenxing You, Coleen Lau, Allen Yu, Yingying Wei, Yunfei Yuan, Paul Bo-San Lai, Jingmin Zhao, Kwan Man, Jun Yu, Michael Kahn, Nathalie Wong
Summary: The study revealed unique mutational processes in the livers of NAFLD-HCC patients, suggesting susceptibility to tumor formation through defective DNA repair pathways. CTNNB1 mutation plays a significant role in immune exclusion, providing important insights for the development of potential therapies.
JOURNAL OF HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Kai Li, Yi Niu, Yichuan Yuan, Jiliang Qiu, Yunxing Shi, Chengrui Zhong, Zhiyu Qiu, Keren Li, Zhu Lin, Zhenkun Huang, Chao Zhang, Dinglan Zuo, Wei He, Yunfei Yuan, Binkui Li
Summary: Insufficient thermal ablation can promote the progression of hepatocellular carcinoma (HCC) and upregulate the E3 ligase Nedd4. Nedd4 enhances the TGF-beta signal transduction, promoting tumor growth and metastasis. High Nedd4 expression correlates with aggressive tumor phenotypes and poor prognosis in HCC patients.
Article
Cell Biology
Xiaoshuang Zhou, Dongtai Chen, Yan Yan, Qiang Li, Wei Xing, Yanling Liu, Yonghua Chen, Dongyin Wang, Yunfei Yuan, Jingdun Xie, Weian Zeng, Jiahao Pan
Summary: This study reveals that NOP plays an oncogenic role in hepatocellular carcinoma (HCC) and is associated with clinicopathological features and survival outcomes of HCC patients. NOP overexpression promotes HCC growth, while its antagonist, JTC801, inhibits NOP function and could potentially be used as a drug for HCC therapy.
CELL DEATH DISCOVERY
(2022)
Article
Oncology
Shuaitong Zhang, Shengyu Huang, Wei He, Jingwei Wei, Lei Huo, Ningyang Jia, Jianbo Lin, Zhenchao Tang, Yunfei Yuan, Jie Tian, Feng Shen, Jun Li
Summary: This study aimed to investigate the role of a radiomics-based method in predicting lymph node (LN) metastasis for patients with intrahepatic cholangiocarcinoma (ICC). The results showed that this method provided accurate prediction of LN metastasis and prognostic assessment for ICC patients, and could potentially aid in preoperative surgical decision-making.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Cell Biology
Yuanping Zhang, Dinglan Zuo, Jiliang Qiu, Kai Li, Yi Niu, Yichuan Yuan, Yuxiong Qiu, Liang Qiao, Wei He, Chenwei Wang, Yunfei Yuan, Binkui Li
Summary: This study reveals that nucleoredoxin plays a significant role in suppressing the proliferation and metastasis of hepatocellular carcinoma (HCC) by inhibiting the deubiquitylation of Snail protein, suggesting a potential therapeutic approach for the treatment of HCC metastasis.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Lei Wen, Zhigang Chen, Xiaomeng Ji, William Pat Fong, Qiong Shao, Chao Ren, Yanyu Cai, Binkui Li, Yunfei Yuan, Deshen Wang, Yuhong Li
Summary: CRLM patients with POLE EDM exhibit distinct clinical characteristics and extremely high TMB, and show significant clinical response to ICI-based combination therapy. Complete sequencing of POLE exonuclease domains is recommended in CRLM patients clinically.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Chemistry, Multidisciplinary
Chengrui Zhong, Yi Niu, Wenwu Liu, Yichuan Yuan, Kai Li, Yunxing Shi, Zhiyu Qiu, Keren Li, Zhu Lin, Zhenkun Huang, Dinglan Zuo, Zhiwen Yang, Yadi Liao, Yuanping Zhang, Chenwei Wang, Jiliang Qiu, Wei He, Yunfei Yuan, Binkui Li
Summary: This study identifies S100A9 as a key driver for post-TACE HCC progression by promoting mitochondrial fission and reactive oxygen species production. Higher S100A9 levels are associated with worse prognosis in HCC patients.
Editorial Material
Gastroenterology & Hepatology
Wei He, Binkui Li, Yunfei Yuan
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)